Greg serves as Co-chair of the Private Equity Practice, where he advises clients across technology, health care, consumer products, retail, and industrial sectors on the legal and strategic complexities of acquisitions, exits, and growth investments. Known for his practical, business-minded approach, Greg guides clients through structuring deals, negotiating terms, and managing risk with clarity and efficiency.

His work spans the full life cycle of private equity investments, from initial platform acquisitions to bolt-on transactions and liquidity events. Greg’s practice focuses on helping private equity sponsors, portfolio companies, and other investors navigate complex M&A deals, recapitalizations, and restructurings.

He began his career in corporate law with a passion for driving business growth through strategic transactions and has since built a reputation for delivering results that align with his clients' objectives.

Outside of his professional work, Greg is a proud Cornell wrestling alum. His two sons now wrestle at Columbia, continuing a family tradition that holds deep personal significance — a topic he’s always happy to discuss.

Represented Charlesbank Capital Partners in its acquisition of Q6 Intelligence, an intelligence and fraud prevention services provider; its strategic investment in IMPLAN Group LLC, a provider of economic impact data and analytical software; strategic growth investment in Quorum Cyber, a global cybersecurity firm; investment in Searchlight Cyber, a UK-based dark web intelligence company; investment in Solve Advisors, an SaaS-based database tool for financial services companies; and acquisition of ImageQuix Holdings, LLC, a software company for high-volume photo studios.
Represented Artemis Capital Partners in multiple transactions, including its acquisitions of Richland Glass, an Advanced Materials manufacturer of specialty glass containment products and solutions; Diamond Antenna and Microwave Corporation, a developer of advanced radio frequency and electro-mechanical solutions for mission critical applications at the frontier of national security, connectivity, and mobility; SightLine Applications, LLC, a developer of image processing electronics and software products; Tekscan, Inc., a manufacturer of flexible, ultra-thin sensors and systems; R.M. Lucas Co., a manufacturer of coatings and mastics; and McDanel Advanced Ceramic Technologies LLC, a manufacturer of high quality industrial and advanced technical ceramics.
Represented DW Healthcare Partners in multiple transactions, including its organization of a continuation vehicle to extend DW’s investment in its portfolio company, Med Learning Group, a continuing medical education company; its acquisition of ownership interests in Cefaly Technology SPRL and Cefaly US Inc., a medical device company; its acquisition of a controlling stake in Aequor Healthcare Services, a New Jersey–based healthcare and IT staffing company; its sale of Med-Pharmex, Inc., a California-based pharmaceutical research, formulation, and manufacturing company in the animal health industry, to Dechra Pharmaceuticals; and its sale of WillowWood Global LLC, a leading designer and manufacturer of a broad range of prosthetic products, to Blue Sea Capital.
Represented a fund in its $1.1 billion leveraged buyout of a construction manufacturer of bridge, drainage, earth stabilization, and stormwater solutions.
Represented a fund in its $223 million sale of a specialized large-scale bakery to another fund.
Represented a fund in its leveraged buyout of a global supplier of mobile audio-video accessories, installation and fabrication supplies, and OEM integration solutions.
Represented a fund in its leveraged buyout of a manufacturer of custom engineered protective covers, truck roll-up doors, and cable/hose carriers.
Represented a fund in its leveraged buyout of a manufacturer and fabricator of custom hose, conveyor belt, sealing/safety products with operations in the US and Canada.
Represented a fund in its sale of a cement, ready mix concrete, aggregate, asphalt production company to a large strategic acquirer.
Represented a health care–focused fund in its $130 million leveraged buyout of a wound company.
Represented a large fund in its $550 million sale of a large-scale dialysis company to another private equity company.
Represented a health care–focused private equity company in its $330 million leveraged buyout of two clinical medical laboratories.
Represented one of Europe’s leading independent music publishers in its $250 million acquisition of a well-renowned Broadway-based administrator and promoter of entertainment copyrights as well as the rights to the songs and musicals of certain legendary Broadway songwriters.
Represented a private equity company in its $23 million leveraged buyout of a restaurant chain.
Represented a private equity sponsor in the $70 million leveraged buyout of a hair care company.
Represented a portfolio company of a large private equity sponsor in the acquisition of a drug development company, with contingent consideration, based on success of the product, up to $400 million.

Read less

2025 Private Equity Trends Outlook

November 19, 2024 | Blog | By Gregory Fine, Kari Harris, Kurt Steinkrauss, Matthew T. Simpson

Learn more about important trends in 2025 for the private equity landscape, including the expansion of continuation vehicles as a vital liquidity tool, heightened regulatory scrutiny and antitrust pressures introducing both challenges and opportunities, and interest rate cuts and evolving buyer-seller risk tolerance creating a more complex deal environment.

May 16, 2014 | Alert | By Gregory Fine, Jessica Mendoza

Survival of representations and warranties (“reps and warranties”) is among the staples of highly negotiated provisions in M&A purchase agreements. The length of the survival period limits the time during which claims may be brought for breaches of reps and warranties.

Read less